Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Person › Details

Arthur Lahr (Kiadis Pharma N.V. (Euronext: KDS))

Lahr, Arthur (Kiadis 201704– CEO before Crucell 200701 Chief Strategy Officer + EP Sales + BusDev)


Organisations Organisation Kiadis Pharma N.V. (Euronext: KDS)
  Group Kiadis (Group)
  Former/major organisation Crucell N.V. (Euronext: CRXL, Nasdaq: CRXL)
  Group Johnson & Johnson (JnJ) (Group)
Product Product ATIR™ (Kiadis)
Document Source Kiadis Pharma N.V.. (6/13/17). "Press Release: Kiadis Pharma Raises €5 Million in Private Placement with Institutional Investors [Not for US, AU, CA, JP, ZA or any other jurisdiction where unlawful]". Amsterdam.

Record changed: 2019-11-13


Picture [iito] – Putting Information into Context 650x65px

More documents for Arthur Lahr

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75

» top